Regeneron partners with Parabilis on antibody-Helicon conjugates, pays USD 50 million upfront

Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc.

REGN

0.00
  • Regeneron entered a strategic research collaboration with Parabilis Medicines to discover and develop multiple therapeutic candidates using Parabilis’ Helicon peptide platform, with a focus on Antibody-Helicon Conjugates targeting historically hard-to-drug intracellular proteins.
  • Parabilis will receive USD 125 million, consisting of a USD 50 million upfront payment, a USD 75 million equity investment commitment tied to its next financing.
  • The deal includes up to about USD 2.2 billion in potential development, regulatory, and commercial milestones across five initial targets, with tiered royalties up to the low double-digits on future net sales.
  • Regeneron will lead development, manufacturing, and worldwide commercialization for any medicines that emerge from the collaboration.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regeneron Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605180700PRIMZONEFULLFEED9721821) on May 18, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.